Trial · NCT07077525
Registered outcomes17
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 17 of 17
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Evaluation of HbA1c level | 0,6 and 12 months of treatment | Measurement of serum levels of HbA1C as a percentage (%) at 0 (baseline) 6 and 12 months. Change of serum level of HbA1C due to treatments after 12 months and determine the frequency of participants achieved reduction of HbA1c level by more than 1% |
| Primary | Evaluation of serum level of FBG | 0, 6 and 12 months | Measurement of serum level of FBG as (mg/dl) at 0,6 and 12 months. Change of serum level of FBG due to treatments after 12 months |
| Primary | Evaluation of serum level of PPG | 0.6 and 12 months | Measurement of serum level of PPG as (mg/dl) at 0,6 and 12 months. Change of serum level of PPG due to treatments after 12 months |
| Secondary | Evaluation of Body mass index (BMI) | 0,6 and 12 months of treatment | Change in body mass index (kg/m2) due to different treatments from baseline to 6, and 12 months. |
| Secondary | Evaluation of serum inflammatory cytokines | 0 and 12 months of treatment | Assessment of serum level of interleukin 8 (IL8), nitric oxide (NO) and tumor necrosis factor subtype alpha (TNF-α) at baseline and 12-months post treatment |
| Secondary | Assessment of genetic variation | After 12 months of treatment | Genotyping assays among participant of study and its relation to glycemic control and other cardiovascular risk factors for certain genes SNP rs6741949 in the DPP4 gene, SNP rs6923761 in the GLP1 receptor and SNP rs2285676, in the KATP gene. |
| Secondary | Assessment of lipid profile parameters | 0, 6 and 12 months of treatment | Measurement of lipid profile parameters at 0 (baseline) 6 and 12 months. Change of lipid profile parameters due to different treatments from baseline to 12 months of treatment |
| Secondary | Assessment of a common variant, SNP rs6741949, in the DPP4 gene | After 12 months of treatment | Assessment of a common variant, SNP rs6741949, in the DPP4 gene to determine the highest frequency and responsive alleles |
| Secondary | Assessment of a common variant SNP rs6923761, in the GLP1 receptor | After 12 months of treatment | Assessment of a common variant SNP rs6923761, in the GLP1 receptor to determine the highest frequency and responsive allele. |
| Secondary | Assessment of a common variant, SNP rs2285676, in the KATP gene. | After 12 months of treatment | Assessment of a common variant, SNP rs2285676, in the KATP gene to determine the highest frequency and responsive allele. |
| Other | Measurement of homocysteine and vitamin B12 serum levels | 0 and 12 months | . Assessment of homocysteine and vitamin b12 was in serum at 0 and 12 months |
| Other | Measurement of stromal cell derived factor and vascular cell adhesion molecule 1 in serum | 0 and 12 months of treatment | Serum level of stromal cell derived factor 1 alpha (SDF-1α) as a biomarker of CV risk and mortality was determined at 0 and 12 months |
| Other | Evaluation of serum liver biomarkers | 0, 6 and 12 months of treatment | Serum liver biomarkers \[alanine aminotransferase (ALT), aspartate aminotransferase (AST), direct and total bilirubin\] will be assessed using standard colorimetric techniques |
| Other | Assessment of serum creatinine (sCr) | 0 and 12 months of treatment | Measurement of serum creatinine (mg/dl) at 0 and 12 months of treatment to determine the change of serum creatinine due to different treatments from baseline to 12 months of treatment |
| Other | Measurement of albumin/creatinine ratio | 0 and 12 months of treatment | Measurement of albumin/creatinine ratio (mg/g) at 0 and 12 months of treatment to determine the change of A/c ratio due to different treatments from baseline to 12 months of treatment |
| Other | Assessment of eGFR | 0 and 12 months of treatment | Measurement of eGFR (ml/min) at 0 and 12 months of treatment to determine the change of eGFR due to different treatments from baseline to 12 months of treatment |
| Other | Assessment of CrCl | 0 and 12 months of treatment | Measurement of CrCl (ml/min) at 0 and 12 months of treatment to determine the change of CrCl due to different treatments from baseline to 12 months of treatment |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07077525/registered